Capricor Therapeutics' stock plummeted after an FDA Advisory Committee voted against the effectiveness of its Duchenne muscular dystrophy (DMD) cell therapy, Deramiocel, citing insufficient evidence. This rejection casts significant doubt on the therapy's approval prospects and has severely impacted investor confidence.
The FDA Advisory Committee's 9-3 vote against Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy is a major setback for the company. The panel's concerns about insufficient evidence and post hoc changes to trial analyses directly contradict the company's claims of effectiveness, despite recent peer-reviewed publication of HOPE-3 data. This event significantly reduces the likelihood of FDA approval for Deramiocel, leading to a massive sell-off in CAPR stock. For traders, this represents a severe negative catalyst, with short-term implications of continued downward pressure and long-term uncertainty regarding the company's pipeline and future prospects.